TICKERNERD
Menu
AXSMAXSMHealthcare · Biotechnology

AXSM Stock Forecast: Axsome Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$174
−1.55% on the day

The 22 Wall Street analysts covering Axsome Therapeutics, Inc. hold a median 12-month price target of $278 — +59.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 5 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$9.4B
Ticker Nerd rank
70 / 100
Median analyst target
$278
Analysts covering
22
Revenue$218.4M+45.5% y/y
Operating income−$51.1M
Net income−$51.3M
Free cash flow−$33.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.3%
1M
−15.6%
YTD
−4.5%
1Y
+45.4%
From 52W high
−31.7%
From 52W low
+46.9%
$119
$255
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AXSM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Axsome Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
94
Quality
92
Value
91
Momentum
73
Accruals
64
Growth
61
Issuance
39
Revisions
36
Size
16

Volatility (94): The share price has been relatively steady.

Revisions (36): Analysts have, on balance, been cutting their forecasts.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AXSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AXSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250$300$350$400Jan 26Apr 26Jul 26Oct 26AXSMHigh $380Median $278Low $246

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
21 Buy1 Hold0 Sell
Low $246Median $278High $380

The green dot is the last close — the median target sits +59.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
29 Sept 2026Deutsche BankMaintainsBuy$280 → $267
25 Sept 2026Morgan StanleyMaintainsEqual-Weight$251 → $247
23 Sept 2026Truist SecuritiesMaintainsBuy$200 → $285
18 Sept 2026Piper SandlerReiteratesOverweight$258
18 Sept 2026Piper SandlerReiteratesOverweight—
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$290
31 Aug 2026HC Wainwright & Co.ReiteratesBuy—
12 Aug 2026MizuhoMaintainsOutperform$306 → $316
12 Aug 2026MizuhoMaintainsOutperform—
11 Aug 2026GuggenheimMaintainsBuy—
11 Aug 2026GuggenheimMaintainsBuy$260 → $275
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$242 → $251
11 Aug 2026Morgan StanleyMaintainsEqual-Weight—
11 Aug 2026NeedhamMaintainsBuy—
11 Aug 2026NeedhamMaintainsBuy$267 → $268
11 Aug 2026RBC CapitalMaintainsOutperform$304 → $297
11 Aug 2026RBC CapitalMaintainsOutperform—
11 Aug 2026Wells FargoMaintainsOverweight—
11 Aug 2026Wells FargoMaintainsOverweight$255 → $256
31 July 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXSM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AXSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Axsome Therapeutics, Inc. returned +45.4% against +16.6% for the S&P 500, dividends included.

AXSM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Jan 26Apr 26Jul 26Oct 26AXSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AXSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
6
Fundamentals

Axsome Therapeutics, Inc. (AXSM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−48.7×

Cheaper than 98% of US stocks

Price / sales
12.1×

Cheaper than 13% of US stocks

Price / book
112.5×

Cheaper than 1% of US stocks

EV / EBITDA
−53.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
45.5%

Higher than 85% of US stocks

Earnings growth (YoY)
45.5%

Higher than 73% of US stocks

Gross margin
93.8%

Higher than 98% of US stocks

Operating margin
−23.4%

Higher than 21% of US stocks

Net margin
−24.7%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−245.1%

Higher than 6% of US stocks

Return on assets
−16.3%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Axsome Therapeutics, Inc. (AXSM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Axsome Therapeutics, Inc. has a market value of $9.4B and an enterprise value of $9.3B.

  • Revenue in the twelve months to 30 June 2026: $776.6M. The latest quarter grew 45.5% year on year.

  • Net income over the same four quarters: −$191.6M, a −24.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.75.

  • Free cash flow in the twelve months to 30 June 2026: −$72.0M.

  • Shares outstanding: 52.3M.

  • Trailing P/E: −48.7×; forward P/E: 35.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Axsome Therapeutics, Inc. employs 1,346 people — $577K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

AXSM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AXSMAxsome Therapeutics, Inc.$9.4B
70
KYMRKymera Therapeutics, Inc.$9.1B
72
PTGXProtagonist Therapeutics, Inc.$9.0B
97
ARWRArrowhead Pharmaceuticals, Inc.$8.7B
55
CYTKCytokinetics, Inc.$8.7B
49
CAICaris Life Sciences, Inc.$8.6B
35
TGTXTG Therapeutics, Inc.$8.6B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Axsome Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AXSM news & analysis

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

The Motley Fool · 1 Oct 2026neutral

The Motley Fool published a comparison article examining Axsome Therapeutics and Vertex Pharmaceuticals as potential investments for 2026. The article highlights Axsome's explosive revenue growth as it scales its commercial portfolio for central nervous system disorders, while noting Vertex's profitability, dominance in cystic fibrosis, and expanding gene therapy reach.

Why it matters — This piece contextualizes Axsome's commercial growth for central nervous system disorders against a large biotech peer, offering AXSM watchers a benchmark for evaluating the company's market position.

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day

GlobeNewsWire · 21 Sept 2026neutral

Axsome Therapeutics announced results of the Shared Goals: Navigating Alzheimer's Agitation survey, conducted by The Harris Poll in collaboration with CaringKind, which was presented at Psych Congress 2026 in New Orleans in connection with World Alzheimer's Day. The survey found that 97% of care partners reported agitation negatively impacted their loved one's quality of life, and three in four wished they had recognized symptoms sooner.

Why it matters — For Axsome, a CNS-focused biopharmaceutical company, this survey highlights the burden of Alzheimer's disease agitation, a condition relevant to its therapeutic pipeline and patient-caregiver community.

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

Benzinga · 21 Sept 2026neutral

U.S. stocks settled mixed on Friday, with the Nasdaq Composite gaining more than 100 points during the session while the Dow Jones settled lower and recorded its worst week since March. The item notes that Wall Street's most accurate analysts weighed in on five stocks in the spotlight last week, including Axsome Therapeutics.

Why it matters — Axsome Therapeutics was one of the five stocks highlighted by Wall Street's most accurate analysts, so an AXSM watcher would be interested in seeing analyst attention on the company.

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction

MarketBeat · 19 Sept 2026positive

Axsome Therapeutics reported accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation. Management also expects operating expenses to remain relatively stable in the second half of the year.

Why it matters — AXSM watchers would care because it signals growing commercial traction for AUVELITY alongside a stable cost outlook for the remainder of the year.

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

MarketBeat · 19 Sept 2026positive

Axsome Therapeutics executives presented at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting growth across its commercial portfolio, an expanded sales force, and multiple late-stage clinical programs including Auvelity.

Why it matters — AXSM watchers would care because the presentation underscores momentum in the company's commercial products and progress across several promising late-stage pipeline candidates.

FAQ

Frequently asked questions about AXSM stock

What is the AXSM stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Axsome Therapeutics, Inc. have a median 12-month price target of $278, with estimates ranging from $246 to $380. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AXSM stock a buy right now?

Of the 22 analysts covering Axsome Therapeutics, Inc., 21 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axsome Therapeutics, Inc. 70 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AXSM?

As at 5 Oct 2026, Axsome Therapeutics, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).

Will AXSM stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +59.5% from the last close, and Ticker Nerd's factor model ranks Axsome Therapeutics, Inc. 70 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AXSM stock forecast for 2030?

No analyst covering Axsome Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $246 to $380 over the next 12 months.

How has AXSM stock performed over the past year?

Axsome Therapeutics, Inc. returned +45.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Axsome Therapeutics, Inc. do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.

What is the latest news on AXSM?

The most recent item we track (The Motley Fool, 1 Oct 2026): "Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?". The Motley Fool published a comparison article examining Axsome Therapeutics and Vertex Pharmaceuticals as potential investments for 2026. The article highlights Axsome's explosive revenue growth as it scales its commercial portfolio for central nervous system disorders, while noting Vertex's profitability, dominance in cystic fibrosis, and expanding gene therapy reach.

Company

About Axsome Therapeutics, Inc.

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.

CEO Dr. Herriot Tabuteau M.D. · 1,346 employees · United States · https://www.axsome.com